AMW welcomes Ilse Aigner, President of the Bavarian State Parliament, at the Warngau site to share a success story
Warngau, Germany, April 11, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, was delighted to welcome today the President of the Bavarian State Parliament, Ilse Aigner, to its headquarters in Warngau near Munich, Germany. In her speech to AMW employees, Ms. Aigner acknowledged the Company’s innovative strength and emphasized the importance of the bio-pharmaceutical industry for Bavaria as an attractive business location. This was Ms. Aigner’s second visit to AMW since 2017, at that time in her capacity as Minister of State for Economic Affairs and Media, Energy and Technology.
“We are delighted to welcome Ms. Aigner here in Warngau once again,” said Philipp Karbach, CEO of AMW. “As a successful company, we are relying on a supportive business environment to further execute on our growth strategy. To be competitive in international markets, political support from the Bavarian authorities is a decisive factor. AMW underwent significant changes since Ms. Aigner last visited almost seven years ago. We are progressing well on our growth path, and we successfully focused our portfolio to manufacturing high-quality implants for global markets. We are therefore particularly honored that Ms. Aigner wanted to personally visit AMW and experience our innovative strength and the commitment of our highly qualified employees.”
After a professional exchange with AMW executives on the strategic focus, prospects and business environment to support the Company’s intended growth course, Ms. Aigner visited selected production facilities. In her speech to AMW employees following the plant tour, she emphasized the importance of the bio-pharmaceutical industry for Bavaria as an innovation hub. Ilse Aigner, President of the Bavarian State Parliament, said: “It is impressive to see how mid-sized Bavarian companies are competing in a global environment. AMW is an excellent example of how innovative strength, entrepreneurial foresight and highly experienced employees lead to mid- and long-term success.”
###
About AMW:
AMW GmbH is a specialty bio-pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.
AMW is based in Warngau near Munich, Germany.
For further information please contact:
AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
E-Mail: news@a-m-w.eu